AbbVie Inc.: EPS $3.82 vs $3.73 expected; revenue $17.4B vs $17.3B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 3.82 | 3.73 | +2.4% | 1.86 |
| Revenue (USD bn) | 17.40 | 17.32 | +0.5% | 15.78 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Q3 FY2026 | 3.82 | 3.73 | +2.4% | 17.40 | 17.32 | +0.5% |
| Jul 31, 2026 | Q2 FY2026 | 3.65 | 3.61 | +1.1% | 16.99 | 16.80 | +1.1% |
| Apr 29, 2026 | Q1 FY2026 | 2.65 | 2.59 | +2.3% | 15.00 | 14.72 | +1.9% |
| Feb 4, 2026 | Q4 FY2025 | 2.71 | 2.65 | +2.3% | 16.62 | 16.41 | +1.2% |
| Oct 31, 2025 | Q3 FY2025 | 1.86 | 1.77 | +5.1% | 15.78 | 15.59 | +1.2% |
| Jul 31, 2025 | Q2 FY2025 | 2.97 | 2.88 | +3.1% | 15.42 | 15.03 | +2.6% |
| Apr 25, 2025 | Q1 FY2025 | 2.46 | 2.38 | +3.4% | 13.34 | 12.93 | +3.2% |
| Jan 31, 2025 | Q4 FY2024 | 2.16 | 2.98 | −27.5% | 15.10 | 14.83 | +1.8% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
AbbVie Inc. results: EPS $3.82 vs $3.73 expected; revenue $17.4B vs $17.3B. The results cover the company's Q3 FY2026. Reported EPS came in above analysts' estimate by 2.4%, and it includes a one-off item the company's release names; revenue above the estimate by 0.5%.
According to the company's results release, EPS includes an unfavorable impact of $0.11 per share from acquired IPR&D and milestones expense.
Revenue was up 10.3% from $15.8 billion a year earlier (Q3 FY2025). EPS was up 105.4% from $1.86 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
According to the company's results release, management raised its financial outlook.
AbbVie Inc. operates a pharmaceutical portfolio spanning immunology, inflammation, oncology, gastroenterology, and neurology. Revenue growth indicates expanding sales across the company, but the supplied information does not identify which treatments drove that growth or how broadly it extended across therapeutic areas.
Understanding the business depends on demand for its medicines and its ability to turn research and development into commercially viable treatments. Its varied portfolio makes the sales mix and the costs of drug development, manufacturing, and commercialization important to understanding the relationship between revenue growth and profitability.
What to watch on the earnings call: Watch for management's explanation of the sources of sales growth and the role of immunology, oncology, and the rest of the portfolio in demand. Discussion of how product mix and spending on research, development, manufacturing, and commercialization affect margins would also help clarify the contribution of each therapeutic area.
For the full analysis of AbbVie Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.